Kalevi Kurkijarvi Sells 2,000 Shares of FibroGen Inc (FGEN) Stock
FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $42.80, for a total transaction of $85,600.00. Following the completion of the sale, the director now directly owns 22,000 shares in the company, valued at $941,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Tuesday, December 12th, Kalevi Kurkijarvi sold 12,000 shares of FibroGen stock. The shares were sold at an average price of $44.45, for a total transaction of $533,400.00.
- On Friday, November 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $46.65, for a total transaction of $93,300.00.
- On Tuesday, October 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $52.24, for a total transaction of $104,480.00.
Shares of FibroGen Inc (FGEN) traded up $1.20 during trading on Thursday, hitting $44.55. 484,200 shares of the stock traded hands, compared to its average volume of 627,022. FibroGen Inc has a fifty-two week low of $19.25 and a fifty-two week high of $60.15. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.
A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price objective for the company. Finally, Jefferies Group restated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.67.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.